|
Colon Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Using these nm23 locus-specific CA repeats and five other chromosome 17 loci (D17S1522, D17S1566, D17S855, D17S515, and TP53), allele loss was observed in 4/32 (12.5%) patients with colon cancer, 2/14 (14.3%) with gastric cancer, and 1/7 (14%) with germ cancer.
|
9341864 |
1997 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Novel combination therapy for human colon cancer with adenovirus-mediated wild-type p53 gene transfer and DNA-damaging chemotherapeutic agent.
|
9359484 |
1997 |
|
Colon Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
It is hypothesized that the development of colon carcinoma during pregnancy can be attributed to alterations of the p53 tumor suppressor gene or gene product on one hand and a maternal immune-tolerant state on the other.
|
9062163 |
1997 |
|
Colon Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mutation frequencies at codon 248 of the p53 tumour suppressor gene are not increased in colon cancer cell lines with the RER+ phenotype.
|
9278485 |
1997 |
|
Colon Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A p53 mutation increased the risk of death by 2.82 times in patients with stage II and by 2.39 times in patients with stage III colon carcinoma.
|
9108757 |
1997 |
|
Colon Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In the 125 cases studied, there were 53 tumors with mutations of the p53 gene. p53 mutations correlated with lymph node metastases from right colon carcinoma cases (61%), and all cases with p53 mutations and microsatellite instability were AJCC/UICC Stage III (Dukes Stage C).
|
9731891 |
1998 |
|
Colon Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In the present study, a large family with evidence of polyposis and colon cancer was screened for the mutations of the p53 gene and protein overexpression.
|
9732936 |
1998 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Interestingly, an enhanced p53 protein induction response was observed in HCT116 3-6 (MLH1+) compared with HCT116 (MLH1-) cells after IR or 6-TG.
|
9485033 |
1998 |
|
Colon Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The correlation between p53 mutations and the histological status of the samples suggest the involvement of this genetic event in the development of colon cancer in patients with ulcerative colitis.
|
9533753 |
1998 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results demonstrated a progressive immunoreactivity for PCNA in the HP to AC sequence, while p53 positivity and aneuploidy seemed specific for colon carcinoma.
|
9673389 |
1998 |
|
Colon Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These results suggest that alterations in the tumour suppressor gene p53 may inhibit TSP1 expression in colon cancer.
|
9849855 |
1998 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Isolation of a novel TP53 target gene from a colon cancer cell line carrying a highly regulated wild-type TP53 expression system.
|
9713990 |
1998 |
|
Colon Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Differential photosensitivity in wild-type and mutant p53 human colon carcinoma cell lines.
|
9540217 |
1998 |
|
Colon Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
KM12L4 and SW620, human colon cancer cell lines with p53 mutations, were transduced with a replication-defective adenoviral vector containing the wild-type p53 gene (Ad5/CMV/p53).
|
9622060 |
1998 |
|
Colon Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expressions of p53 and proliferating cell nuclear antigen (PCNA) were studied immunohistochemically from paraffin sections of 7 cases (9 lesions) of radiation-induced colon cancer and 42 cases of spontaneous colon cancer.
|
9610028 |
1998 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The effect of p53 disruption on Taxol sensitivity was explored further in the breast carcinoma MCF-7 and colon carcinoma HCT-116 cell lines that had been stably transfected with either the human papillomavirus type-16 E6 gene or a dominant-negative mutant p53 gene.
|
9563901 |
1998 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
UV-irradiated plasmids were transfected into a human RKO colon carcinoma cell line that contains wild-type (wt) p53 as well as its derivatives, either mutant p53-143ala (RKO-143ala) or human papillomavirus E6 (RKO-E6, a wt p53 protein that is rapidly degraded and non-functional).
|
10074921 |
1999 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Identification of seven genes regulated by wild-type p53 in a colon cancer cell line carrying a well-controlled wild-type p53 expression system.
|
10691030 |
1999 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We applied the differential mRNA display method to isolate genes regulated by wild-type TP53 in cells of a colon-cancer line (SW480) in which we had established an inducible TP53 expression system under the control of the lactose operon.
|
10534768 |
1999 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have studied the possible interactions between the mismatch repair system and p53 in a human colon cancer cell line, HCT-116 (known to have a homozygous mutation in mismatch repair gene hMLH1 on chromosome 3) and in a clone obtained after insertion of a single copy of chromosome 3 (HCT-116+ ch3).
|
10213232 |
1999 |
|
Colon Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Colon cancer: p53 expression and DNA ploidy. Their relation to proximal or distal tumor site.
|
10477366 |
1999 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have examined the effects of commonly used chemotherapeutic agents on human colon cancer cell lines in which the p53 pathway has been specifically disrupted by targeted homologous recombination.
|
10430607 |
1999 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Multiple factors other than p53 influence colon cancer sensitivity to paclitaxel.
|
11052631 |
2000 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We studied 5-FU- and ZD1694-induced TS inhibition in relation to the expression of p53, p21, Bcl-2 and Bax in six colon carcinoma cell lines, two with a wild-type (wt) p53 (Lovo, LS174T) and four with a mutant (mt) p53 (WiDr, WiDr/F, HT29 and SW948) phenotype.
|
10785598 |
2000 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We assessed the hypothesis that a compromised p53 function could account for the non response of colon cancer patients with low thymidylate synthase (TS) expression receiving a bolus 5-fluorouracil (5-FU) leucovorin (LV) combination.
|
11038045 |
2000 |